{"preliminary_commentary":{"by_channel":{"x_thread":8,"podcast":7,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00417079\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["cabazitaxel"]],"indication":"metastatic castration-resistant prostate cancer after docetaxel treatment","name":"TROPIC","nct_id":"NCT00417079","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropic-nct00417079. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TROPIC","arms":[{"description":"Mitoxantrone + Prednisone","label":"Mitoxantrone + Prednisone","type":"ACTIVE_COMPARATOR"},{"description":"Cabazitaxel + Prednisone","label":"Cabazitaxel + Prednisone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2009-09","type":"ACTUAL"},"conditions":["Neoplasms","Prostatic Neoplasms"],"enrollment":{"count":755,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"cabazitaxel (XRP6258) (RPR116258)","otherNames":["Jevtana"],"type":"DRUG"},{"name":"mitoxantrone","otherNames":[],"type":"DRUG"},{"name":"prednisone","otherNames":[],"type":"DRUG"}],"last_update":"2011-03-10","lead_sponsor":"Sanofi","official_title":"A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2009-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From the date of randomization up to 104 weeks (study cut-off)"}],"references":[{"citation":"Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015 Apr;26(4):750-755. doi: 10.1093/annonc/mdu587. Epub 2014 Dec 23.","pmid":"25538172","type":"DERIVED"},{"citation":"Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, de Bono JS, Sartor AO; TROPIC Investigators. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013 Sep;24(9):2402-8. doi: 10.1093/annonc/mdt194. Epub 2013 May 30.","pmid":"23723295","type":"DERIVED"},{"citation":"Pouessel D, Oudard S, Gravis G, Priou F, Shen L, Culine S. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. Bull Cancer. 2012 Jul-Aug;99(7-8):731-41. doi: 10.1684/bdc.2012.1608. French.","pmid":"22743148","type":"DERIVED"},{"citation":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.","pmid":"20888992","type":"DERIVED"}],"start_date":{"date":"2007-01"},"study_type":"INTERVENTIONAL","title":"XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT00417079"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropic-nct00417079"}